

INDEX

- Accelerated or mass spectrometry (AMS), 301, 597
- Accurate mass measurement, 342, 584
- Accurate radioisotope counting (ARC), 298
- Active metabolite, 215, 250, 251, 253, 257
detection of, 251, 353
screening of, 354, 356
- Adenosine phosphate phosphosulfate (APPS), 419
- Adenosine triphosphate (ATP)-binding cassette, 138
- ADME, 261–270, 573
- Alcohol dehydrogenases (ADH), 25
- Aldehyde dehydrogenases (ALDH), 25
- Aldehyde oxidase, 23, 24
- Aldo-keto reductases (AKR), 28
- Antioxidant response element (ARE), 54, 73
- Atmospheric pressure chemical ionization (APCI), 322
- Atmospheric pressure ionization (API)
interfaces, 320
methods, 321
- Atmospheric pressure photoionization (APPI), 323
- Bile duct cannulated (BDC) animals, 271, 575
- Bile salt export pump (BSEP), 153
- Bilirubin, 38, 279
- Bioactivation, 353, 448
species-specific, 279
- Bioassay-guided methods, 253
- Biopharmaceutics classification system (BCS), 171
- Bioreactors, 6, 585
- Biotransformation, 5, 6
characterization, 413
technique, 253
- Biphasic kinetics, 97, 101, 430, 431
- Blood–brain barriers (BBB), 149
- Branched DNA signal amplification technology (bdNA), 554
- Breast cancer resistance protein (BCRP), 138, 152, 225
- Carboxylesterases (CES), 483
- Cell-based assays, 116, 178, 253, 552

- Central nervous system (CNS), 149
Cerebrospinal fluid (CSF), 149
Chloramphenicol acetyl transferase (CAT), 559
Collision-induced dissociation (CID), 354, 453
Common technical document (CTD), 211, 263
Competitive inhibition, 102, 104, 107, 109, 223
Conjugation enzymes, 224
Conjugation reaction, 251
 phenotyping, 484
Constant neutral loss (CNL), 354
Constant neutral loss scan (CNLS), 329, 451
Continuous wave (CW) spectroscopy, 369
Counts per minute (CPM), 293, 583
CYP-dependent metabolism, 534
Cytosolic sulfotransferases, 61
- Dansyl glutathione (dGSH), 457
Data-dependent acquisition (DDA), 345
Deconjugation, 66
Dehydroepiandrosterone sulfate (DHEAS), 184
Desorption atmospheric pressure chemical ionization (DAPCI), 325
Desorption electrospray ionization (DESI), 324
Dipole–dipole interaction, 382
Direct analysis in real-time (DART), 325
Disintegrations per minute (DPM), 290, 583
Distortionless enhancement by polarization transfer (DEPT), 585
DNA binding domain (DBD), 122, 549
Dose selection and formulation, 578
Dosimetry, 597–602
Double-reciprocal plot, 92, 94
Drug absorption, 139
 role of transporters in, 139, 158, 171, 184
Drug disposition, 12
 role of transporters in, 139
Drug–drug interaction (DDI), 8, 59, 70, 113, 119, 137, 157, 171, 172, 175, 176, 203, 208, 218–220, 230, 246, 261, 262, 281, 514, 546, 548
 factors affecting, 537
 inhibition-mediated, 116
 magnitude of, 484
 metabolism-dependent, 545
 potential, 502
 transporter-mediated, 175
 quinidine-digoxin interaction, 171
 transporter-related, 158
Drug–food interactions, 158, 173, 184, 240
Drug glucuronidation, 61
Drug metabolism, 239, 240, 261, 262
 impact, 7
 in drug development, 261
 in vitro, 218, 219, 274
 reaction, 251, 477
 transporters in, 150
Drug metabolizing enzyme(s), 59, 89, 125, 224, 414, 488, 513, 518, 546–550
 identification of, 275
 induction of, 278
Dubin–Johnson syndrome, 153
Dynamic flow HPLC-RFD, 300
 transporters in, 158
- Eadie–Hofstee plot, 94, 101, 427, 431
Electrospray-assisted laser desorption ionization (ELDI), 325
Electrospray ionization (ESI), 321, 452, 458, 470
Electrostatic analyzer (ESA), 326
Endogenous substrates, 38, 39
Enzyme catalysis, 90, 114
Enzyme inhibition, 114, 514, 534
Enzyme kinetics, 89, 101, 128, 290, 310
 characterization of, 413, 425
 determination of, 89
Enzyme-selective substrates, 485
Enzyme-specific index reaction, 498
Enzyme-specific inducer, 551
Enzyme–substrate complex, 90, 91, 104, 105
Epoxide hydrolase, 29, 30
 mechanism, 30
Erythromycin breath test, 563, 564
Esterase inhibitors, 55
European Agency for the Evaluation of Medicinal Products (EMA), 208
European Medicinal Evaluation Agency (EMA), 204
- Farnesoid X receptor (FXR), 122
Fast Fourier transforms (FFTs), 328

- First-pass metabolism, 252
Fish-odor syndrome, 21
Flavin-containing monooxygenase (FMO), 16, 20, 481, 485
Flow scintillation analyzer (FSA), 338
Fluorescence chromatograms, 458
Fluorescent assay, 532
FMO-catalyzed reactions, 242
Fourier transform ion cyclotron resonance (FTICR), 325
Fourier transform mass spectrometer (FTMS), 328
Free induction decay (FID), 372
- Gemfibrozil, 129, 280
Gemfibrozil-*O*-glucuronide, 129
Genetic polymorphisms, 54, 157, 262
Gilbert's syndrome, 54
Glucuronidation, 37, 59, 61
Glutathione conjugates, 82, 349
 metabolism, 83
 screening, 354
Glutathione disulfide, 457, 468
Glutathione peroxidase (GPX), 29
Glutathione-S-transferases (GSTs), 54, 70, 73
Glycolipids, 39
Good clinical practices (GCP), 210
Good laboratory practice (GLP), 209, 515, 574
- Heme-thiolate proteins, 546
Heterotropic activation, 99
High performance liquid chromatography (HPLC), 57, 66, 320, 387, 580
High throughput screening (HTS), 414, 514
HIV protease inhibitors, 279
HMG-CoA reductase inhibitor, 129
HPLC-based radiochromatographic techniques, 290
HPLC-microplate scintillation counting (MSC), 291
HPLC-UV chromatography, 243
Human-specific signaling molecules, 550
Hydroxylated polychlorinated biphenyls (HPCBs), 70
- Inductively coupled plasma MS (ICPMS), 349
- In silico* methods, 244
Institutional Animal Care and Use Committee (IACUC), 466
Investigational New Drug Application (IND), 210
International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), 204, 266, 281
Investigative Review Board (IRB), 268
Investigator's brochure (IB), 210
In vitro assays, 182, 184, 552, 565
In vitro covalent protein binding, 462, 464
 protocol, 462
In vitro CYP reaction, 129
In vitro-in vivo correlation, 92, 175, 185, 241, 438, 439
 procedure of, 435
 transporter-based, 175
In vitro-in vivo scaling techniques, 478
In vitro-ligand binding, 253
In vitro metabolite profiling, 212, 275
Ion chromatograms, 303, 321, 330, 594
 MDF-treated, 597
Ion evaporation model (IEM), 322
Ion-trap mass spectrometer, 452
Iron-sulfur protein, 29
Irreversible inhibition, 114, 116, 526
Isotopic stability, 499
- Kitz-Wilson plot, 110
Krebs-bicarbonate buffer, 464, 469
 optimization of, 517
- Lamotrigine (LTG), 59
Ligand binding domain (LBD), 122, 549
Linear ion trap (LIT) MS, 327
Lineweaver-Burk plot, 92, 427
Liquid chromatography-tandem mass spectrometry (LC/MS/MS), 329
Liquid radiochromatographic techniques, 214
Liquid scintillation counter (LSC), 268, 290, 578
Liquid scintillation techniques, 575
- Madin-Darby canine kidney (MDCK), 179
Mapping transporter substrates, 181

- Mass analyzers, 325–329
 beam-type, 325
 ion-trapping, 325
Mass balance, 586
Mass defect filter (MDF), 346, 348, 584
Mechanism-based inhibition, (MBI), 526
 kinetic model, 528
Membrane-based assays, 176
Metabolic activation, 448
 pathways, 319, 346, 447
Metabolite in safety testing (MIST), 208, 273, 574
Metabolite profiling, 245, 270, 583, 591
 analytical methods, 213
Michaelis–Menten equation, 90, 91, 103
Michaelis–Menten kinetics, 90, 425, 514
Microarray technology, 532
Microplate scintillation counting (MSC), 583
Ministry of Health, Labor and Welfare in Japan (MHLW), 209
Mitoxantrone resistance protein (MXR), 138
Monoamine oxidase (MAO), 22, 482
Multidrug resistance-associated proteins (MRP), 225
Multiple reaction-monitoring (MRM), 521
Myelodysplastic syndrome (MDS), 155
Myeloperoxidase, 246
- N-acetyltransferases (NATs), 484
NADPH-P450 reductase, 27
Nanospray ionization (NSI), 343
New chemical entities (NCEs), 116, 413, 448, 478, 513
New drug application (NDA), 210, 281
New radiochromatography techniques, 293
NMR (1D), 381, 383
 Chemical shifts, 375, 377
 Coupling constants, 378
 NOE, 382, 383
 Water suppression, 385, 397
NMR hardware, 372
NMR spectroscopy, 5, 348, 380, 381
NMR spectrum, 373, 381
Noncompetitive inhibition, 104
Noncytochrome p450 reaction phenotyping, 481
- Nonsteroidal anti-inflammatory drugs (NSAIDs), 172
Northern blot, 554, 555
Nuclear magnetic resonance (NMR), 369
Nuclear overhauser experiment (NOE), 382
Nuclear receptors (NRs), 122
Nucleotide binding domains (NBDs), 138
- Online radiochromatographic technique, 298, 308
Online radioflow detection (RFD), 290
Oral therapy, 239
Organic anion transporter (OAT), 225
Organic anion transporting polypeptide (OATP), 225
Organic cation transporter (OCT), 225
- Paraoxonases (PON), 483
Parkinson's disease-type syndrome, 22
Peroxidases, 24, 25
Peroxisome proliferator-activated receptor (PPAR), 54
Pharmaceutical Research and Manufactures of America (PhRMA), 514
Pharmacodynamic (PD) inhibition, 513
Pharmacokinetic optimization, 8
Phenacetin metabolic pathways, 251
Plasma concentration–time curve, 438, 588
Polycyclic aromatic hydrocarbon (PAH), 28
Precursor ion scan (PIS), 329
Pregnane X receptor (PXR), 181
Probenecid, 60
PXR-dependent induction pathway, 553
PXR reporter gene assays, 557, 560, 562
- Quadrupole ion trap (QIT), 327
Quadrupole mass analyzer, 326
Quantitative whole body autoradiography (QWBA), 268
Quinone reductase (NQO), 28
- Radioactive isotopes, 289
Radioactivity recovery determination, 298
Radiochromatography techniques, 290, 293
Radiolabeled drugs, 575

- Radiometric assays, 65
- Reaction phenotyping, 477
- N-acetylation reaction phenotyping, 487
 - Nonradiolabeled reaction phenotyping, 489
 - Quantitative reaction phenotyping using metabolite standard, 497
 - UGT reaction phenotyping, 484, 486
- Reactive metabolites, 218
- Relative activity factor (RAF), 497
- Retinoid X receptor (RXR), 122
- Reversible CYP inhibition, 534
- Rizatriptan, 483
- Scintillation proximity assay (SPA), 552
- SDS–polyacrylamide gel electrophoresis, 555
- Secretory placental alkaline phosphatase (SPAP), 559
- Selected/multiple reaction monitoring (SRM/MRM), 329
- Short-interfering RNA (iRNA), 155
- Single ion monitoring (SIM), 515
- Single nucleotide polymorphisms (SNPs), 157
- role of, 157
- Soft ionization technique, 322
- Software-assisted metabolite identification, 345
- Solute carrier (SLC), 138
- Solvent suppression techniques, 385
- Species-specific PXR receptor, 550
- Standard operating procedures (SOP), 574
- Steroid xenobiotic receptor (SXR), 181
- Stop-flow HPLC-RFD, 298, 310
- Sulfation reaction phenotyping, 488
- Sulfonation, 70
- Sulfotransferases (SULTs), 484
- Tandem mass spectrometry, 329, 330
- Thin-layer chromatography (TLC), 57
- Time-dependent inhibition, 220
- Tissue distribution, 268, 597, 602
- Total radioactivity (TRA), 270
- Transmembrane domains (TMDs), 138
- Transporter-mediated efflux, 184
- Transporter phenotyping, 488
- Transporter proteins, 137–139, 566
- Trans-species enzyme systems, 6
- Trapping-type analyzers, 325
- Trifluoroacetic acid (TFA), 82, 388, 463
- Trimethylamine (TMA) metabolism, 482
- Tritium-labeled drugs, 575
- UDP-glucuronosyltransferases (UGTs), 37, 481
- Ultra-performance liquid chromatography (UPLC), 301
- Ultraviolet (UV) absorbance, 493
- Uncompetitive inhibition, 105
- Uridine diphosphate glucuronic acid (UDPGA), 308, 418
- binding site, 39
- Valproic acid, 59
- Water-soluble drugs, 154
- Western blot analysis, 488, 552
- Western blotting, 76
- Western immunoblotting, 278
- Xanthine dehydrogenase, 23, 24
- Xenobiotic disposition, 6
- metabolism, 8, 546
- Xenobiotic-induced toxicity, 9
- Xenobiotics, 340, 404, 452
- bioactivation of, 218, 461, 467
 - biotransformation of, 341
 - metabolism of, 546

